All Oncology News

Fangfang Yan, PhD, discusses findings from a multi-omic analysis that identified mechanisms of pirtobrutinib resistance in mantle cell lymphoma.

The FDA has approved Darzalex Faspro plus VRd for select multiple myeloma and several applications are under regulatory review in lung and GI cancers.

Dana M. Chase, MD, Robert Neff, MD, and Maurie Markman, MD, comment on the current state of HPV vaccination and screening during cervical cancer awareness month.

EMA CHMP backs niraparib plus abiraterone with ADT for BRCA1/2-mutant mHSPC, supported by data from the AMPLITUDE study.

OncLive spoke to 4 experts in order to unpack the top data presented during oncology conferences over the course of 2025.

Monitoring thymidine kinase activity levels may provide insights on response to CDK4/6 inhibitor therapy in breast cancer.

An NDA for lirafugratinib in the second line for patients with FGFR2-altered cholangiocarcinoma has been submitted to the FDA.

Kristen Spencer, DO, discusses how patient goals are shaping first-line treatment selection for metastatic pancreatic cancer.

Northwestern Medicine pioneered a total artificial lung system, enabling successful double-lung transplants.

The FDA has accepted a BLA seeking the approval of ivonescimab plus chemotherapy for EGFR-mutated, advanced, nonsquamous NSCLC after TKI progression.

An NDA for rivoceranib plus camrelizumab in frontline HCC has been resubmitted to the FDA, following the company's receipt of 2 CRLs for this indication.

OncLive outlines some of the most notable new agents and combinations to earn FDA approval in 2025, including the topline data supporting these decisions.

IBI3003 received fast track designation from the regulatory agency in the setting of relapsed/refractory multiple myeloma.

The emergence of ultrasensitive ctDNA and CSF testing may help alter monitoring strategies and adaptive clinical trial designs in metastatic breast cancer.

Oncology Fellows spotlights fellows who received research fellowship grants during the 2025 ESMO Congress.

The clinical benefit and disease control rates were both 100% with lurbinectedin plus ipilimumab/nivolumab in patients with advanced soft tissue sarcoma.

Nicholas Polizzi, PhD, and Edward Boyden, PhD, are recipients of the December 2025 Medical Research Grant from the W. M. Keck Foundation.

The gremlin-1–directed monoclonal antibody ginisortamab showed early efficacy signals when combined with SOC therapy in patients with advanced GI tumors.

The FDA has approved a 375-mg vial of nelarabine for intravenous administration in both T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.

Nuvisertib was well tolerated with no dose-limiting toxicities and promising efficacy in relapsed/refractory myelofibrosis.

The predictive value of PD-L1 expression on response to chemoimmunotherapy was greater on metastatic lesions vs primary tumors in HGSOC.

Andrew Yee, MD, and Krina Patel, MD, MSc, discuss up-and-coming oral PI combination regimens in relapsed/refractory multiple myeloma.

The FDA has approved daratumumab and hyaluronidase plus VRd for adult patients with newly diagnosed multiple myeloma who are not eligible for ASCT.

A meta-analysis found rapid progression and hyperprogression with nivolumab plus ipilimumab in renal medullary carcinoma.

Radiation therapy administered prior to surgery rarely shrinks retroperitoneal tumors in sarcoma according to Fox Chase Cancer Center researchers.

The novel oral fascin inhibitor NP-G2-044 received FDA orphan drug designation for patients with pancreatic cancer.

Andrew Yee, MD, and Krina Patel, MD, MSc, discuss updates to the NCCN guidelines and key data updates in relapsed/refractory multiple myeloma.

Guillermo Garcia-Manero, MD, discusses the phase 3 GLORA-4 study of lisaftoclax plus azacitidine in higher-risk MDS.

The resubmission of an sBLA of nogapendekin alfa inbakicept plus BCG in BCG-unresponsive, papillary-only NMIBC was discussed with the FDA.

Sagar Lonial, MD, FACP, FASCO, discusses findings from the CC-220-MM-001 trial of iberdomide plus daratumumab and dexamethasone in newly diagnosed myeloma.